A naturally occurring clinical solution for the early treatment of Parkinson’s Disease.
More than 10 million people worldwide are living with Parkinson’s Disease (PD), including:
Early diagnosis and treatment are critical. Parkinson’s and similar conditions often begin years before the first visible symptoms, and emerging therapies aim to slow progression, preserve brain function, and improve quality of life when introduced early.
PMT will empower healthcare providers with cutting-edge clinical data science solutions, seamless access to cGMP-grade product ordering, and expert training – positioning them to deliver exceptional patient outcomes as soon as regulatory approvals are secured.
PMT is dedicated to improving the lives of Parkinson’s Disease (PD) patients through new therapeutic options, aiming to slow disease progression and enhance quality of life.
The neurodegenerative disease treatment market is projected to reach $40B+ Globally.
Active engagement with FDA (US) and EMA (EU) for approvals.
Partners for preclinical studies and phased trials in place.
Leveraging cutting-edge clinical insights through HIPAA/GDPR compliant data platforms.
Support the novel development of therapeutic API
Relevant industry experience and network.
Become a shareholder in a pioneering company shaping the future of Parkinson’s treatment.
Stay informed about our latest research, clinical trials, and breakthroughs in NAD+ therapy.
